With the advent of targeted agents for the treatment of renal cell carcinoma (RCC), overall
survival has improved, and patients are being treated continuously for increasingly long …

Targeted therapy for advanced renal cell carcinoma (RCC) has recently expanded the
available treatment options for patients with these malignancies. The rapid introduction of …

CONTEXT: The therapeutic scenario for metastatic renal cell carcinoma (mRCC) has been
evolving rapidly, with sunitinib, sorafenib, bevacizumab, everolimus, pazopanib, and …

PURPOSE: In April 2009, an expert group of 11 physicians and clinical nurses met to
discuss the management of selected adverse events associated with the use of everolimus …

Treatment of metastatic renal cell carcinoma (mRCC) has evolved rapidly over the last two
decades as major pathways involved in pathogenesis have been elucidated. These include …

Abstract Learning Objectives After completing this course, the reader should be able to:
Evaluate the recommended clinical doses and the associated safety data for targeted …

Vascular-endothelial growth-factor (receptor)(VEGF)(R)-inhibiting agents–sunitinib [1],[2],[3],
sorafenib [4],[5], pazopanib [2],[6], bevacizumab [7],[8], axitinib [5] and tivozanib [9],[10]–have …

Angiogenesis inhibitors have become standard of care for advanced and/or metastatic renal
cell carcinoma (RCC), but data on the impact of adverse events (AE s) and treatment …

Background: Bevacizumab plus interferon-α2a (IFN) prolongs progression-free survival to>
10 months, which is comparable with sunitinib as first-line treatment of metastatic renal cell …

Background Vascular endothelial growth factor (VEGF), tyrosine kinase (TK) and
mechanistic target of rapamycin kinase (mTOR) inhibitors are common first-line (1 L) …